Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of “Moderate Buy” by Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat reports. Six analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $32.00.

Several equities analysts have recently commented on the company. HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $35.00 to $31.50 in a research note on Thursday, May 28th. Stephens set a $32.00 target price on Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Oppenheimer cut Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. Finally, Citigroup cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $35.00 to $31.50 in a research note on Friday, May 8th.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX opened at $31.36 on Wednesday. The stock has a market cap of $3.84 billion, a PE ratio of 18.02, a P/E/G ratio of 0.95 and a beta of 0.74. Catalyst Pharmaceuticals has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The business has a 50 day moving average price of $29.16 and a two-hundred day moving average price of $25.65.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Public Sector Pension Investment Board increased its holdings in shares of Catalyst Pharmaceuticals by 10.8% during the third quarter. Public Sector Pension Investment Board now owns 516,745 shares of the biopharmaceutical company’s stock valued at $10,180,000 after purchasing an additional 50,343 shares during the period. American Century Companies Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 43.8% during the third quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock valued at $49,805,000 after purchasing an additional 770,198 shares during the period. Rafferty Asset Management LLC increased its holdings in shares of Catalyst Pharmaceuticals by 64.1% during the third quarter. Rafferty Asset Management LLC now owns 157,044 shares of the biopharmaceutical company’s stock valued at $3,094,000 after purchasing an additional 61,328 shares during the period. Royce & Associates LP increased its holdings in shares of Catalyst Pharmaceuticals by 28.6% during the third quarter. Royce & Associates LP now owns 2,034,965 shares of the biopharmaceutical company’s stock valued at $40,089,000 after purchasing an additional 452,103 shares during the period. Finally, Fundsmith LLP increased its holdings in shares of Catalyst Pharmaceuticals by 24.2% during the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock valued at $66,267,000 after purchasing an additional 654,721 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).